Postoperative Dose of Parathyroid Hormone as a Marker for the Occurrence of Hypoparathyroidism After Total Thyroidectomy

Diagnostic Value of Immediate Postoperative Dose of Parathyroid Hormone as a Marker for the Occurrence of Hypoparathyroidism After Total Thyroidectomy: A Retrospective Observational Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02924532

Enrollment

300

Registered

2016-10-05

Start date

2012-02-01

Completion date

2018-12-31

Last updated

2026-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypoparathyroidism

Brief summary

The main objective of this study is to establish an optimal threshold Early parathormon (PTH) assay in order to exclude hypoparathyroidism , that is to say to obtain a negative predictive value of hypoparathyroidism highest possible.

Interventions

BIOLOGICALimmediate post operative bioassay of Parathyroid Hormone

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients consecutively operated on between February 1, 2012 and December 1, 2013 * Total thyroidectomy +/- lymphadenectomy * Respect of clinicobiological protocol presented above * The ( the ) patient ( e) was informed ( e) on the implementation of the study 's objectives, constraints and patient rights * The ( the ) patient ( e) is under ( e) at least 18 years

Exclusion criteria

* The ( the ) patient ( e) is under guardianship, curatorship or under guard saves justice * It is not possible to give to ( the ) patient ( e) informed information * History of cervical radiotherapy * Previous history of dysfunction of the parathyroid glands * Previous history of surgery of the parathyroid glands * A history of kidney failure or hepatocellular * History of osteomalacia or Paget's disease * unhealed cancer antecedent * History of sarcoidosis

Design outcomes

Primary

Measure	Time frame	Description
the presence/absence of hypoparathyroidism	day 1	hypoparathyroidism is defined as: corrected serum calcium Day 1 \<1.90 and / or symptoms of hypocalcemia (cramps, tingling of the extremities and peri-oral) to Day 1 authenticated by a VAS score\> 3.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 19, 2026